Authors' reply

Affiliations

¹ Speciality Doctor and Research Fellow, Institute of Neuroscience, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle-upon-Tyne, NE4 5PL, UK Email: Mourad.wahba@ntw.nhs.uk.
² Speciality Trainee, Regional Affective Disorder Service, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle-upon-Tyne, NE4 5PL, UK.
³ Senior Lecturer and Honorary Consultant Psychiatrist, Academic Psychiatry and Regional Affective Disorder Service, Institute of Neuroscience, Newcastle University, Wolfson Research Centre, Newcastle-upon-Tyne, NE4 5PL, UK.
⁴ Postdoctoral Researcher, Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK.
⁵ Director, Centre for Affective Disorders, Department of Psychological Medicine, NIHR Senior Investigator, Academic Director, Psychological Medicine and Older Adults Clinical Academic Group, President of the British Association for Psychopharmacology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
⁶ Professor of Addiction Biology, Imperial College, Centre for Psychiatry, Imperial College London, UK.

Comment

Mourad Wahba et al. Br J Psychiatry. 2019 Sep.

. 2019 Sep;215(3):568-569.

doi: 10.1192/bjp.2019.171.

¹ Speciality Doctor and Research Fellow, Institute of Neuroscience, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle-upon-Tyne, NE4 5PL, UK Email: Mourad.wahba@ntw.nhs.uk.
² Speciality Trainee, Regional Affective Disorder Service, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle-upon-Tyne, NE4 5PL, UK.
³ Senior Lecturer and Honorary Consultant Psychiatrist, Academic Psychiatry and Regional Affective Disorder Service, Institute of Neuroscience, Newcastle University, Wolfson Research Centre, Newcastle-upon-Tyne, NE4 5PL, UK.
⁴ Postdoctoral Researcher, Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK.
⁵ Director, Centre for Affective Disorders, Department of Psychological Medicine, NIHR Senior Investigator, Academic Director, Psychological Medicine and Older Adults Clinical Academic Group, President of the British Association for Psychopharmacology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
⁶ Professor of Addiction Biology, Imperial College, Centre for Psychiatry, Imperial College London, UK.

No abstract available

Comment on

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F, Cleare AJ, Young AH. Strawbridge R, et al. Br J Psychiatry. 2019 Jan;214(1):42-51. doi: 10.1192/bjp.2018.233. Epub 2018 Nov 20. Br J Psychiatry. 2019. PMID: 30457075
Neurometabolic approach to treatment-resistant depression.
Reynolds EH. Reynolds EH. Br J Psychiatry. 2019 Sep;215(3):568. doi: 10.1192/bjp.2019.170. Br J Psychiatry. 2019. PMID: 31397247 No abstract available.